Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

Silvana Martino, D.O.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: March 13, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 20-509, S-039, Gemzar (Gemcitabine HCl), sponsored by Eli Lilly & Company, proposed indication: for use in combination with Carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	**Nature**	**Magnitude**
Consulting on an Unrelated Matter	Sponsor	Her Employer Receives Less Than $10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

//S// 2/1/06

Signature of SGE Date